View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 4, 2022

BMS’ mavacamten boosts cardiovascular outcomes in obstructive HCM study

The safety profile of the oral therapy in the EXPLORER-LTE cohort was in line with the EXPLORER-HCM trial.

Bristol Myers Squibb (BMS) has reported the latest interim data from the EXPLORER-LTE cohort of the MAVA-LTE study, where mavacamten showed improved cardiovascular outcomes in symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) patients.

An oral investigational therapy, mavacamten is an inhibitor of cardiac myosin.

MAVA-LTE is a dose-blinded, five-year study analysing mavacamten in symptomatic obstructive HCM patients who took part in Phase III EXPLORER-HCM trial.

The EXPLORER-LTE cohort enrolled 231 of the 244 subjects who were qualified to be part of the long-term extension study at the end of EXPLORER-HCM. 

Findings showed that the mavacamten treatment offered clinically meaningful, sustained improvements in left ventricular outflow tract (LVOT) gradients, N-terminal pro brain natriuretic peptide (NT-proBNP) levels and New York Heart Association (NYHA) Class at 48 weeks and up to 84 weeks.

Furthermore, the safety profile of the oral therapy was in line with the EXPLORER-HCM trial.

In the long-term follow-up period, no new safety signals were reported with the exposure adjusted event rates found to be stable or reduced in the cohort.

Bristol Myers Squibb vice-president and mavacamten development programme lead Marie-Laure Papi said: “Interim results from this EXPLORER-LTE cohort build upon the clinical evidence supporting the potential for longer-term use of mavacamten in patients with symptomatic obstructive HCM.

“We look forward to the opportunity to bring this medicine to patients and eagerly await the US Food and Drug Administration’s decision on our New Drug Application later this month.”

According to data from clinical and preclinical studies, mavacamten was found to consistently lower cardiac wall stress biomarkers, reduced excessive cardiac contractility, boosted diastolic compliance and lowered LVOT gradients.

In December last year, BMS reported interim data from the Phase III TRANSFORM trial of Breyanzi (lisocabtagene maraleucel; liso-cel), which boosted outcomes in adult relapsed or refractory large B-cell lymphoma patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU